{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T09:39:52Z","timestamp":1770457192929,"version":"3.49.0"},"reference-count":14,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DD&amp;T"],"published-print":{"date-parts":[[2021,8,31]]},"DOI":"10.5582\/ddt.2021.01068","type":"journal-article","created":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T22:07:14Z","timestamp":1627769234000},"page":"225-226","source":"Crossref","is-referenced-by-count":2,"title":["Less is more: A novel single-tablet regimen with two-drugs, dolutegravir\/lamivudine"],"prefix":"10.5582","volume":"15","author":[{"given":"Jianjun","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Infection and Immunity, Shanghai Public Health Clinical Center, Shanghai, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongzhou","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Infection and Immunity, Shanghai Public Health Clinical Center, Shanghai, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3542","reference":[{"key":"1","unstructured":"1. UNAIDS. Global HIV &amp; AIDS statistics-Fact sheet. <i>https:\/\/www.unaids.org\/en\/resources\/fact-sheet <\/i>(accessed July 20, 2021)."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Nolan D, Mallal S. Complications associated with NRTI therapy: Update on clinical features and possible pathogenic mechanisms. Antivir Ther. 2004; 9:849-863.","DOI":"10.1177\/135965350400900609"},{"key":"3","unstructured":"3. Canadian Agency for Drugs and Technologies in Health. Clinical Review Report: Dolutegravir\/Lamivudine (Dovato): (ViiV Healthcare ULC): Indication: As a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents 12 years of age and older and weighing at least 40 kg. <i>https:\/\/pubmed.ncbi.nlm.nih.gov\/31877000\/ <\/i>(accessed July 20, 2021)."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Riddler SA, Haubrich R, DiRienzo AG, <i>et al<\/i>. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008; 358:2095-2106.","DOI":"10.1056\/NEJMoa074609"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Back D. 2-Drug regimens in HIV treatment: Pharmacological considerations. Germs. 2017; 7:113-114.","DOI":"10.18683\/germs.2017.1115"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Kelly SG, Nyaku AN, Taiwo BO. Two-drug treatment approaches in HIV: Finally getting somewhere? Drugs. 2016; 76:523-531.","DOI":"10.1007\/s40265-016-0553-8"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Fida M, Rizza SA, Temesgen Z. Dolutegravir plus lamivudine dual therapy - A new option for initial antiretroviral therapy. Drugs Today (Barc). 2019; 55:297-304.","DOI":"10.1358\/dot.2019.55.5.2962947"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Cahn P, Madero JS, Arribas JR, <i>et al<\/i>. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): Week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet. 2019; 10167:143-155.","DOI":"10.1016\/S0140-6736(18)32462-0"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Cahn P, Madero JS, Arribas JR, <i>et al<\/i>. Durable efficacy of dolutegravir plus lamivudine in antiretroviral treatment-naive adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 randomized clinical trials. J Acquir Immune Defic Syndr. 2020; 83:310-318.","DOI":"10.1097\/QAI.0000000000002275"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Cahn P, Madero JS, Arribas JR, <i>et al<\/i>. Durable efficacy of dolutegravir (DTG) plus lamivudine (3TC) in antiretroviral treatment-na\u00efve adults with HIV-1 infection: 3-year results from the GEMINI studies. J Int AIDS Soc. 2020 (Suppl. 7). <i>https:\/\/onlinelibrary.wiley.com\/doi\/epdf\/10.1002\/jia2.25616<\/i> (accessed July 25, 2021).","DOI":"10.1016\/j.jiph.2020.01.118"},{"key":"11","unstructured":"11. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services.<i> https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/AdultandAdolescentGL.pdf<\/i> (accessed July 20, 2021)."},{"key":"12","unstructured":"12. European AIDS Clinical Society. EACS Guidelines 2020. <i>https:\/\/www.eacsociety.org\/guidelines\/eacs-guidelines<\/i>\/ (accessed July 20, 2021)."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Butler K, Anderson SJ, Hayward O, Jacob I, Punekar YS, Evitt LA, Oglesby A. Cost-effectiveness and budget impact of dolutegravir\/lamivudine for treatment of human immunodeficiency virus (HIV-1) infection in the United States. J Manag Care Spec Pharm. 2021; 27:891-903.","DOI":"10.18553\/jmcp.2021.27.7.891"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Girouard MP, Sax PE, Parker RA, Taiwo B, Freedberg KA, Gulick RM, Weinstein MC, Paltiel AD, Walensky RP. The cost-effectiveness and budget impact of 2-drug dolutegravir-lamivudine regimens for the treatment of HIV infection in the United States. Clin Infect Dis. 2016; 62:784-791.","DOI":"10.1093\/cid\/civ981"}],"container-title":["Drug Discoveries &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/15\/4\/15_2021.01068\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T01:27:32Z","timestamp":1672968452000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/15\/4\/15_2021.01068\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,31]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.5582\/ddt.2021.01068","relation":{},"ISSN":["1881-7831","1881-784X"],"issn-type":[{"value":"1881-7831","type":"print"},{"value":"1881-784X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,31]]},"article-number":"2021.01068"}}